<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00421993</url>
  </required_header>
  <id_info>
    <org_study_id>RD.06.SPR.18088</org_study_id>
    <nct_id>NCT00421993</nct_id>
  </id_info>
  <brief_title>A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind, Parallel-Group Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel Compared With Adapalene Topical Gel, 0.1%; Benzoyl Peroxide Topical Gel, 2.5% and Topical Gel Vehicle in Subjects With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, double-blind, parallel group study with 12 weeks of
      treatment of acne vulgaris. Efficacy and safety evaluations will be performed at Screening
      (safety only), Baseline and Weeks 1, 2, 4, 8 and 12. All Investigator's Global Assessment
      evaluators and lesion counters must be trained and approved by Galderma. The evaluator of a
      subject should remain the same during the study.

      The primary objective is to demonstrate the superiority in efficacy and assess safety of
      Adapalene/Benzoyl Peroxide Topical Gel (Adapalene/Benzoyl Peroxide Gel) versus Adapalene
      Topical Gel, 0.1% (Adapalene Monad); Benzoyl Peroxide Topical Gel, 2.5% (Benzoyl Peroxide
      Monad) and Topical Gel Vehicle (Gel Vehicle) in the treatment of acne vulgaris for up to 12
      weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success Rate on the Investigator's Global Assessment</measure>
    <time_frame>at week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Inflammatory Lesion Counts</measure>
    <time_frame>from Baseline to week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Noninflammatory Lesion Counts</measure>
    <time_frame>from Baseline to week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Inflammatory Lesion Counts</measure>
    <time_frame>at week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Noniflammatory Lesion Counts</measure>
    <time_frame>at week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total Lesion Counts</measure>
    <time_frame>at week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1670</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adapalene/Benzoyl Peroxide Topical Gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adapalene Topical Gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Benzoyl Peroxide Topical Gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical Gel Vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene/Benzoyl Peroxide</intervention_name>
    <description>Topical Gel, One application daily in the evening for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene</intervention_name>
    <description>Topical Gel,One application daily in the evening for 12 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzoyl Peroxide</intervention_name>
    <description>Topical Gel, one application daily in the evening for 12 weeks</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Gel Vehicle</intervention_name>
    <description>Topical Gel Vehicle,one application daily in the evening for 12 weeks</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A clinical diagnosis of acne vulgaris with facial involvement.

          -  A minimum of 20 but not more than 50 Inflammatory lesions

          -  A minimum of 30 but not more than 100 Noninflammatory lesions

          -  A score of 3 (Moderate) on the Investigator's Global Assessment Scale.

        Exclusion Criteria:

          -  More than one acne nodule or any acne cyst.

          -  Acne conglobata, acne fulminans, secondary acne, or severe acne.

          -  Known previous participation in an Adapalene/Benzoyl Peroxide Topical Gel Trial.

          -  Underlying diseases that require the use of interfering topical or systemic therapy.

          -  Use of prohibited medications prior to the study unless appropriate washout period is
             documented

          -  Use of hormonal contraceptives solely for control of acne
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Graeber, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galderma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Affliated Research Center</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research of Arkansas</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associates in research, Inc.</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697-1385</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marcia J. Glenn, MD and Associates, Dermatology &amp; Laser center, Inc</name>
      <address>
        <city>Marina Del Rey</city>
        <state>California</state>
        <zip>90292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Research Institute</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University at San Francisco Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Weintraub James</name>
      <address>
        <city>Simi Valley</city>
        <state>California</state>
        <zip>93065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The George Washington University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visions Clinical Research</name>
      <address>
        <city>West palm Beach</city>
        <state>Florida</state>
        <zip>33406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Dermatology and Vein Research Center</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SKINQRI</name>
      <address>
        <city>Lincolnshire</city>
        <state>Illinois</state>
        <zip>60069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Welborn Clinic</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dolby Research, LLC</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamzavi Dermatology</name>
      <address>
        <city>Port Huron</city>
        <state>Michigan</state>
        <zip>48060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somerset Skin Clinic</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James Del Rosso, DO - Office of Dr. James Del Russo</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Specialty Group</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derm Research Center of NY, Inc.</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790-2598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zoe Draelos</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OU Health Sciences Center - Dept. of Dermatology</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy, Asthma and Dermatology Research Center, LLC</name>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <zip>97035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37934</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arlington Center for Dermatology</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UTSW Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9190</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch at Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanner Clinic</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Dermatology Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2S 3B3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stratica Medical</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5K 1X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guildford Dermatology Specialists</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>BC V3R 6A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derm Research @ 888 Inc.</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 3Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winnipeg Clinic</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 0N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermadvances Research</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 1R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nexus clinical research</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NewLab Clinical Research</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 4S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ultranova Skin care</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research inc.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bay Dermatology Centre</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>XLR8 Medical Research Inc.</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research Laval Inc.</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7S 2C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research Inc</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siena Medical Research</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G1C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Licca Clinical Research Institute</name>
      <address>
        <city>Augsburg</city>
        <zip>86179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henrik Pres</name>
      <address>
        <city>Berlin</city>
        <zip>10435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meike Schroeder</name>
      <address>
        <city>Berlin</city>
        <zip>14169</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatrice Gerlach</name>
      <address>
        <city>Dresden</city>
        <zip>01097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kloverkorn, Windfried</name>
      <address>
        <city>Gilching</city>
        <zip>82205</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Otto-Von-Guericke-Universitat Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael Sebastian</name>
      <address>
        <city>Mahlow</city>
        <zip>15831</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Dirschka</name>
      <address>
        <city>Wuppertal</city>
        <zip>42275</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Outpatient Dermatology Department DUH</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Margit Simola</name>
      <address>
        <city>Budapest</city>
        <zip>1084</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Outpatient Dermatilogy Department XIX District</name>
      <address>
        <city>Budapest</city>
        <zip>1195</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waldemar Placek</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85096</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DERMED Specjalistyczne Gabinety Lekarskie</name>
      <address>
        <city>Lodz</city>
        <zip>90265</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojceiech Silny</name>
      <address>
        <city>Poznan</city>
        <zip>60355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.galderma.com/</url>
  </link>
  <reference>
    <citation>Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003 Sep;49(3 Suppl):S200-10. Review.</citation>
    <PMID>12963896</PMID>
  </reference>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2007</study_first_submitted>
  <study_first_submitted_qc>January 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2007</study_first_posted>
  <results_first_submitted>January 15, 2009</results_first_submitted>
  <results_first_submitted_qc>March 10, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 11, 2009</results_first_posted>
  <last_update_submitted>October 19, 2009</last_update_submitted>
  <last_update_submitted_qc>October 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2009</last_update_posted>
  <responsible_party>
    <name_title>Michael Graeber, MD, Head of US Development</name_title>
    <organization>Galderma</organization>
  </responsible_party>
  <keyword>Acne vulgaris</keyword>
  <keyword>Adapalene</keyword>
  <keyword>Benzoyl Peroxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzoyl Peroxide</mesh_term>
    <mesh_term>Adapalene</mesh_term>
    <mesh_term>Adapalene, Benzoyl Peroxide Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: First Subject Enrolled October 2006, Last Subject Enrolled July 2007.
Types of locations: Dermatology Clinics, Dermatology Research Centers.</recruitment_details>
      <pre_assignment_details>The specified washout period up to Baseline for TOPICAL facial treatments was 1 week (light therapy/exfoliation/blackhead removal) or 2 weeks (anti-inflammatory drugs/salicylic acid/steroids/antibiotics/laser) and for SYSTEMIC medications was 2 weeks (anti-inflammatory drugs), 4 Weeks (steroids/antibiotics), or 6 months (anti-acne/contraceptives).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Adapalene/Benzoyl Peroxide Gel</title>
          <description>Adapalene/Benzoyl Peroxide Topical Gel</description>
        </group>
        <group group_id="P2">
          <title>Adapalene Gel</title>
          <description>Adapalene Topical Gel</description>
        </group>
        <group group_id="P3">
          <title>Benzoyl Peroxide Gel</title>
          <description>Benzoyl Peroxide Topical Gel</description>
        </group>
        <group group_id="P4">
          <title>Gel Vehicle</title>
          <description>Topical Gel Vehicle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="419"/>
                <participants group_id="P2" count="418"/>
                <participants group_id="P3" count="415"/>
                <participants group_id="P4" count="418"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="366"/>
                <participants group_id="P2" count="369"/>
                <participants group_id="P3" count="363"/>
                <participants group_id="P4" count="361"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="57"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject transportation issues</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adapalene/Benzoyl Peroxide Gel</title>
          <description>Adapalene/Benzoyl Peroxide Topical Gel</description>
        </group>
        <group group_id="B2">
          <title>Adapalene Gel</title>
          <description>Adapalene Topical Gel</description>
        </group>
        <group group_id="B3">
          <title>Benzoyl Peroxide Gel</title>
          <description>Benzoyl Peroxide Topical Gel</description>
        </group>
        <group group_id="B4">
          <title>Gel Vehicle</title>
          <description>Topical Gel Vehicle</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="419"/>
            <count group_id="B2" value="418"/>
            <count group_id="B3" value="415"/>
            <count group_id="B4" value="418"/>
            <count group_id="B5" value="1670"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.5" spread="6.7"/>
                    <measurement group_id="B2" value="18.5" spread="6.3"/>
                    <measurement group_id="B3" value="18.9" spread="6.96"/>
                    <measurement group_id="B4" value="19.2" spread="7.23"/>
                    <measurement group_id="B5" value="19" spread="6.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>12-17 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="233"/>
                    <measurement group_id="B2" value="241"/>
                    <measurement group_id="B3" value="244"/>
                    <measurement group_id="B4" value="243"/>
                    <measurement group_id="B5" value="961"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="171"/>
                    <measurement group_id="B4" value="175"/>
                    <measurement group_id="B5" value="709"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="236"/>
                    <measurement group_id="B2" value="229"/>
                    <measurement group_id="B3" value="230"/>
                    <measurement group_id="B4" value="244"/>
                    <measurement group_id="B5" value="939"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="185"/>
                    <measurement group_id="B4" value="174"/>
                    <measurement group_id="B5" value="731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="185"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="179"/>
                    <measurement group_id="B4" value="185"/>
                    <measurement group_id="B5" value="734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="101"/>
                    <measurement group_id="B5" value="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="136"/>
                    <measurement group_id="B4" value="132"/>
                    <measurement group_id="B5" value="533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Success Rate on the Investigator's Global Assessment</title>
        <description>Percentage of subjects rated “Clear” and “Almost Clear” on 5-point scale (0=clear; 4=severe)</description>
        <time_frame>at week 12</time_frame>
        <population>Intention to treat (ITT), last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Adapalene/Benzoyl Peroxide Gel</title>
            <description>Adapalene/Benzoyl Peroxide Topical Gel</description>
          </group>
          <group group_id="O2">
            <title>Adapalene Gel</title>
            <description>Adapalene Topical Gel</description>
          </group>
          <group group_id="O3">
            <title>Benzoyl Peroxide Gel</title>
            <description>Benzoyl Peroxide Topical Gel</description>
          </group>
          <group group_id="O4">
            <title>Gel Vehicle</title>
            <description>Topical Gel Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rate on the Investigator's Global Assessment</title>
          <description>Percentage of subjects rated “Clear” and “Almost Clear” on 5-point scale (0=clear; 4=severe)</description>
          <population>Intention to treat (ITT), last observation carried forward (LOCF).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="418"/>
                <count group_id="O3" value="415"/>
                <count group_id="O4" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.9"/>
                    <measurement group_id="O2" value="21.8"/>
                    <measurement group_id="O3" value="26.7"/>
                    <measurement group_id="O4" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Inflammatory Lesion Counts</title>
        <description>Changes in Inflammatory Lesion Counts equals Week 12 Inflammatory Lesion Counts minus Baseline Inflammatory Lesion Counts</description>
        <time_frame>from Baseline to week 12</time_frame>
        <population>ITT, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Adapalene/Benzoyl Peroxide Gel</title>
            <description>Adapalene/Benzoyl Peroxide Topical Gel</description>
          </group>
          <group group_id="O2">
            <title>Adapalene Gel</title>
            <description>Adapalene Topical Gel</description>
          </group>
          <group group_id="O3">
            <title>Benzoyl Peroxide Gel</title>
            <description>Benzoyl Peroxide Topical Gel</description>
          </group>
          <group group_id="O4">
            <title>Gel Vehicle</title>
            <description>Topical Gel Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Inflammatory Lesion Counts</title>
          <description>Changes in Inflammatory Lesion Counts equals Week 12 Inflammatory Lesion Counts minus Baseline Inflammatory Lesion Counts</description>
          <population>ITT, LOCF</population>
          <units>Lesion count</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="418"/>
                <count group_id="O3" value="415"/>
                <count group_id="O4" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18" lower_limit="-49" upper_limit="50"/>
                    <measurement group_id="O2" value="-15" lower_limit="-49" upper_limit="50"/>
                    <measurement group_id="O3" value="-16" lower_limit="-63" upper_limit="38"/>
                    <measurement group_id="O4" value="-12" lower_limit="-47" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Noninflammatory Lesion Counts</title>
        <description>Change in Noninflammatory Lesion Counts equals Week 12 Noninflammatory Lesion Count minus Baseline Noninflammatory Lesion Count</description>
        <time_frame>from Baseline to week 12</time_frame>
        <population>ITT, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Adapalene/Benzoyl Peroxide Gel</title>
            <description>Adapalene/Benzoyl Peroxide Topical Gel</description>
          </group>
          <group group_id="O2">
            <title>Adapalene Gel</title>
            <description>Adapalene Topical Gel</description>
          </group>
          <group group_id="O3">
            <title>Benzoyl Peroxide Gel</title>
            <description>Benzoyl Peroxide Topical Gel</description>
          </group>
          <group group_id="O4">
            <title>Gel Vehicle</title>
            <description>Topical Gel Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Noninflammatory Lesion Counts</title>
          <description>Change in Noninflammatory Lesion Counts equals Week 12 Noninflammatory Lesion Count minus Baseline Noninflammatory Lesion Count</description>
          <population>ITT, LOCF</population>
          <units>Lesion count</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="418"/>
                <count group_id="O3" value="415"/>
                <count group_id="O4" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28" lower_limit="-93" upper_limit="108"/>
                    <measurement group_id="O2" value="-24" lower_limit="-96" upper_limit="44"/>
                    <measurement group_id="O3" value="-23" lower_limit="-87" upper_limit="61"/>
                    <measurement group_id="O4" value="-18" lower_limit="-82" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Inflammatory Lesion Counts</title>
        <description>Percent Changes in Inflammatory Lesion Counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100</description>
        <time_frame>at week 12</time_frame>
        <population>ITT, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Adapalene/Benzoyl Peroxide Gel</title>
            <description>Adapalene/Benzoyl Peroxide Topical Gel</description>
          </group>
          <group group_id="O2">
            <title>Adapalene Gel</title>
            <description>Adapalene Topical Gel</description>
          </group>
          <group group_id="O3">
            <title>Benzoyl Peroxide Gel</title>
            <description>Benzoyl Peroxide Topical Gel</description>
          </group>
          <group group_id="O4">
            <title>Gel Vehicle</title>
            <description>Topical Gel Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Inflammatory Lesion Counts</title>
          <description>Percent Changes in Inflammatory Lesion Counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100</description>
          <population>ITT, LOCF</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="418"/>
                <count group_id="O3" value="415"/>
                <count group_id="O4" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-61.7" spread="33.9"/>
                    <measurement group_id="O2" value="-50.1" spread="39.4"/>
                    <measurement group_id="O3" value="-52.2" spread="39.4"/>
                    <measurement group_id="O4" value="-40.8" spread="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Noniflammatory Lesion Counts</title>
        <description>Percent Changes in Noninflammatory Lesion Counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100</description>
        <time_frame>at week 12</time_frame>
        <population>ITT, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Adapalene/Benzoyl Peroxide Gel</title>
            <description>Adapalene/Benzoyl Peroxide Topical Gel</description>
          </group>
          <group group_id="O2">
            <title>Adapalene Gel</title>
            <description>Adapalene Topical Gel</description>
          </group>
          <group group_id="O3">
            <title>Benzoyl Peroxide Gel</title>
            <description>Benzoyl Peroxide Topical Gel</description>
          </group>
          <group group_id="O4">
            <title>Gel Vehicle</title>
            <description>Topical Gel Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Noniflammatory Lesion Counts</title>
          <description>Percent Changes in Noninflammatory Lesion Counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100</description>
          <population>ITT, LOCF</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="418"/>
                <count group_id="O3" value="415"/>
                <count group_id="O4" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-55.6" spread="35.3"/>
                    <measurement group_id="O2" value="-46.0" spread="33.7"/>
                    <measurement group_id="O3" value="-44.1" spread="37.3"/>
                    <measurement group_id="O4" value="-32.3" spread="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total Lesion Counts</title>
        <description>Percent Changes in Total Lesion Counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100</description>
        <time_frame>at week 12</time_frame>
        <population>ITT, LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Adapalene/Benzoyl Peroxide Gel</title>
            <description>Adapalene/Benzoyl Peroxide Topical Gel</description>
          </group>
          <group group_id="O2">
            <title>Adapalene Gel</title>
            <description>Adapalene Topical Gel</description>
          </group>
          <group group_id="O3">
            <title>Benzoyl Peroxide Gel</title>
            <description>Benzoyl Peroxide Topical Gel</description>
          </group>
          <group group_id="O4">
            <title>Gel Vehicle</title>
            <description>Topical Gel Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total Lesion Counts</title>
          <description>Percent Changes in Total Lesion Counts equals (Week 12 count minus Baseline count) divided by Baseline count multiplied by 100</description>
          <population>ITT, LOCF</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="418"/>
                <count group_id="O3" value="415"/>
                <count group_id="O4" value="418"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.7" spread="31.9"/>
                    <measurement group_id="O2" value="-47.5" spread="31.3"/>
                    <measurement group_id="O3" value="-47.2" spread="32.7"/>
                    <measurement group_id="O4" value="-35.2" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Adapalene/Benzoyl Peroxide Gel</title>
          <description>Adapalene/Benzoyl Peroxide Topical Gel</description>
        </group>
        <group group_id="E2">
          <title>Adapalene Gel</title>
          <description>Adapalene Topical Gel</description>
        </group>
        <group group_id="E3">
          <title>Benzoyl Peroxide Gel</title>
          <description>Benzoyl Peroxide Topical Gel</description>
        </group>
        <group group_id="E4">
          <title>Gel Vehicle</title>
          <description>Topical Gel Vehicle</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (6.1)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="419"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="418"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="415"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="415"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (6.1)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="419"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="418"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="415"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="93" subjects_affected="90" subjects_at_risk="419"/>
                <counts group_id="E2" events="61" subjects_affected="60" subjects_at_risk="418"/>
                <counts group_id="E3" events="37" subjects_affected="35" subjects_at_risk="415"/>
                <counts group_id="E4" events="22" subjects_affected="22" subjects_at_risk="418"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Following the expiration of twenty-four (24) months after the completion of the Study, Investigator shall have the right to publish the results of the Study; provided, however that Sponsor shall have the right to review any proposed publication generated from the Study prior to publication or presentation. The Sponsor shall have the absolute right to refuse the publication altogether, to delay it or to amend its contents as it deems fit.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Graeber, MD</name_or_title>
      <organization>Galderma</organization>
      <phone>609-860-8201</phone>
      <email>michael.graeber@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

